ADC Therapeutics Investor Relations Material
Latest events
Study Update
ADC Therapeutics
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from ADC Therapeutics SA
Access all reports
ADC Therapeutics SA is a biotechnology company specialized in the development of antibody-drug conjugates (ADCs) for the treatment of hematologic malignancies and solid tumors. Its proprietary technology focuses on highly potent, targeted therapies designed to significantly improve patient outcomes by selectively targeting and killing cancer cells. One of the key products offered by ADC Therapeutics is Zynlonta, a CD19-directed ADC for the treatment of certain types of B-cell lymphoma in adult patients. This focus on ADC technology highlights the company's commitment to advancing cancer treatment through innovation. The company is headquartered in Lausanne, Switzerland, and its shares are listed on the NYSE.
Key slides for ADC Therapeutics SA
Study Update
ADC Therapeutics SA
Q1 2025
ADC Therapeutics SA
Latest articles
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
Ticker symbol
ADCT
Country
🇺🇸 United States